AUS
NZ
UK
CA
USA
IND
Highlight
- SG Americas Securities LLC expanded its stake in Sanofi (NASDAQ:SNY) by 19.5% in the fourth quarter, holding 18,008 shares worth $869,000.
- Other major investment firms, including Charles Schwab, JPMorgan Chase, and Geode Capital, also significantly increased their holdings.
- Sanofi's stock performance varies with a market cap of $134.43 billion and a P/E ratio of 27.03; it opened at $52.97 recently.
Sanofi (NASDAQ:SNY), a leading player in the healthcare sector, has witnessed heightened interest from institutional investors, as indicated by several shifts in stock holdings recently reported. SG Americas Securities LLC, in a notable move, increased its position in Sanofi by 19.5% during the fourth quarter. This acquisition brought their total holdings to 18,008 shares, valued at approximately $869,000.
The allure of Sanofi has not been confined to SG Americas Securities alone. Charles Schwab Investment Management Inc. expanded its stake by an impressive 31.1% during the third quarter, bringing its total holdings to 139,505 shares valued at $8,040,000. Similarly, Geode Capital Management LLC and JPMorgan Chase & Co. exhibited confidence in Sanofi's potential, increasing their holdings by 7.1% and 20.9%, respectively.
Despite these positive movements from institutional investors, there have been adjustments from analysts regarding Sanofi's stock ratings. Notably, StockNews.com recently downgraded Sanofi from a "buy" to a "hold" rating in a research report.
Sanofi’s stock opened at $52.97 recently and has been fluctuating, with its 50-day moving average at $48.90 and a 200-day moving average of $52.22. The company has a market capitalization of $134.43 billion with a P/E ratio of 27.03, signaling its substantial presence in the market. Additionally, Sanofi maintains a debt-to-equity ratio of 0.17, indicating a stable financial posture.
Renowned for its diversified operations, Sanofi is engaged in the research, development, manufacture, and marketing of various therapeutic solutions. Its operational segments include Pharmaceuticals, Vaccines, and Consumer Healthcare, catering to areas such as oncology, diabetes, and cardiovascular diseases. With a firm grounding in multiple healthcare verticals, Sanofi is well-positioned to leverage future industry opportunities.
